Exactly. The cost effectiveness was the same whether GRADE was used or not, and whether outcomes were rated low or not -- because it was based on triallists' own published data, not any subjective assessment of that data. And by their own data, they proved their own treatment wasn't cost...
I guess not. Or they're desperate enough to throw caution to the wind.
They never do. They don't want to show themselves up, presumably.
It's an operationalised version of the IOM. Personally, I don't think it's significantly different, though I can see why others would disagree. I certainly...
Please also send these sort of things to Charles at the MEA, if he doesn't have the info already. He's good at reaching out and putting their responses into the public domain.
Thanks for this. Another one to watch.
And you are very good at it! Each point could have been a video of its own, TBF.
It's quite frustrating that they don't engage; they just shout.
I am reminded again of the reports I received from the roundtable. Everyone went in prepared and armed with facts... except for the "complainants"...
Thanks for this. It's useful context, I think.
Abilify can have some strong side effects, so please be vigilant and report anything unusual you note as early as possible. (Hopefully you'll be fine.)
Good luck with your care!
I agree. The wording is designed to sound reasonable. It's certainly less offensive than older stuff. In some ways, that's better if it leads to fewer people holding offensive views, but it still doesn't address the core problems.
We should be getting better quality trials and we shouldn't be...
I mean, we knew they'd do this. But it's still a galling display of "piss-taking", as my late Nana would say.
Ideologues digging their heels in, despite best practice leaving them behind.
Still, anyone treated by them might be in for a huge windfall if they can organise class action against...
No problem. It helps that early on I remembered it all in quite a lot of detail, and putting it down in writing helps me to retain that detail, so it becomes a positive feedback loop.
The more I write about it all, the more I remember.
Many apologies, Trish! I was confused by being tagged in multiple threads at once, and thought you were suggesting following up with NICE.
Hence my response was primarily about the COI process and whether this paper represented Chris Burton's views at the time or not, or whether those views...
Thanks everyone! I thought I was wittering on, as per usual, but my husband was quietly playing the PlayStation in the background (I've shifted my office from the cold spare room to the dining room table), and he said I got across a lot of information in a short space of time. There was loads...
Edit: Answered the wrong thing. Deleted most of my post and summarised the relevant parts to spare you all the eyestrain.
For the record, I don't think Chris Burton could have negatively influenced discussions on trial design (and if he tried, he failed, because we pointed out those flaws...
It's "good patient"/"bad patient" binarism. They see themselves as a good patient, who got better due to their own positivity, and therefore everyone who stays ill is a bad patient.
It's an age old trope.
NICE recently told me that they are incredibly proud of the guideline and think they did it right. They are also working on implementation and raising awareness of the GL, so I can't see them backtracking on it.
All these arguments are recycled ones that we've responded to at length. They never...
I should add: her familiar (in its inaccuracy) way of using references suggests someone has provided her a list to use. There may be some nobbling/coaching/briefing going on.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.